Sun Pharmaceutical Organon Deal: Global and domestic nrokerages have turned increasingly constructive on Sun Pharmaceutical Industries following its announcement to acquire Organon & Co., citing the deal’s strategic fit, earnings accretion and strong cash‑flow profile. Several analysts have raised their target prices on the stock and now peg upside of up to 16 per cent from current levels, highlighting portfolio diversification into women’s health and biosimilars, cost and revenue synergies, and long‑term improvement in scale and profitability.
Notably, shares of Sun Pharmaceutical Industries surged more than 9 per cent on Monday, extending their strong recent run after the acquisition. The rally pushed the stock to within touching distance of its all‑time high of Rs 1,851.20, hit on May 2, leaving it just about 4 per cent below peak levels.
Motilal Oswal On Sun Pharma
Morgan Stanley on Sun Pharma
Nuvama On Sun Pharmaceuticals
Sun Pharma announced an agreement to acquire Organon & Co. in an all‑cash deal valued at USD 11.75 billion. The proposed acquisition, priced at USD 14 per Organon share, marks Sun Pharma’s biggest overseas buy and positions the Indian drugmaker as a top‑10 global player in biosimilars, the deal also strengthens its presence in women’s health and established branded generics across key global markets.
Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021, Sun Pharma said in an exchange filing.
A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimilars, commercialised across 140 countries, with the U.S., Europe, China, Canada, and Brazil among its largest markets. This global footprint is supported by six manufacturing facilities across the European Union and emerging markets.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
